Cells (Dec 2021)

Decrease of Pro-Angiogenic Monocytes Predicts Clinical Response to Anti-Angiogenic Treatment in Patients with Metastatic Renal Cell Carcinoma

  • Stephane Oudard,
  • Nadine Benhamouda,
  • Bernard Escudier,
  • Patrice Ravel,
  • Thi Tran,
  • Emeline Levionnois,
  • Sylvie Negrier,
  • Philippe Barthelemy,
  • Jean François Berdah,
  • Marine Gross-Goupil,
  • Cora N. Sternberg,
  • Petri Bono,
  • Camillo Porta,
  • Ugo De Giorgi,
  • Omi Parikh,
  • Robert Hawkins,
  • Martin Highley,
  • Jochen Wilke,
  • Thomas Decker,
  • Corinne Tanchot,
  • Alain Gey,
  • Magali Terme,
  • Eric Tartour

DOI
https://doi.org/10.3390/cells11010017
Journal volume & issue
Vol. 11, no. 1
p. 17

Abstract

Read online

The modulation of subpopulations of pro-angiogenic monocytes (VEGFR-1+CD14 and Tie2+CD14) was analyzed in an ancillary study from the prospective PazopanIb versus Sunitinib patient preferenCE Study (PISCES) (NCT01064310), where metastatic renal cell carcinoma (mRCC) patients were treated with two anti-angiogenic drugs, either sunitinib or pazopanib. Blood samples from 86 patients were collected prospectively at baseline (T1), and at 10 weeks (T2) and 20 weeks (T3) after starting anti-angiogenic therapy. Various subpopulations of myeloid cells (monocytes, VEGFR-1+CD14 and Tie2+CD14 cells) decreased during treatment. When patients were divided into two subgroups with a decrease (defined as a >20% reduction from baseline value) (group 1) or not (group 2) at T3 for VEGFR-1+CD14 cells, group 1 patients presented a median PFS and OS of 24 months and 37 months, respectively, compared with a median PFS of 9 months (p = 0.032) and a median OS of 16 months (p = 0.033) in group 2 patients. The reduction in Tie2+CD14 at T3 predicted a benefit in OS at 18 months after therapy (p = 0.04). In conclusion, in this prospective clinical trial, a significant decrease in subpopulations of pro-angiogenic monocytes was associated with clinical response to anti-angiogenic drugs in patients with mRCC.

Keywords